TRD

Optimi Health Secures Import Permit from Mind Medicine Australia for MDMA and Psilocybin Capsules

Retrieved on: 
onsdag, maj 29, 2024
Partnership, Patient, MMA, FRA, PTSD, MDMA, TRD, Ground substance, Health Canada, Psilocybin, Entrepreneurship, GMP, Pharmaceutical industry

Mind Medicine Australia, a partner with Optimi since February 2023, achieved a world-first last year by successfully advocating for the rescheduling of MDMA for the treatment of PTSD and psilocybin for treatment-resistant depression (TRD).

Key Points: 
  • Mind Medicine Australia, a partner with Optimi since February 2023, achieved a world-first last year by successfully advocating for the rescheduling of MDMA for the treatment of PTSD and psilocybin for treatment-resistant depression (TRD).
  • "Australian psychiatrists can now prescribe Optimi’s MDMA and psilocybin capsules for therapeutic use in patients, which is a very humbling achievement," remarked JJ Wilson, Co-Founder and Chair of Optimi Health.
  • "Securing the import permits to receive Optimi's MDMA and psilocybin capsules marks a significant step forward in our mission.
  • Mind Medicine Australia is dedicated to ensuring that psychedelic-assisted therapies are available to psychiatrists and patients at the most cost-effective rates.

atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates

Retrieved on: 
onsdag, maj 15, 2024
Patient, Pharmacokinetics, PD, Part Two, Addiction, Investment, DMT, Depression, Anxiety, PTSD, Drug development, Mental health, Part 1, IPO, Entrepreneurship, TRD, OTF, Part, Research, Therapy, G&A, Knowledge, Biotechnology, Pivotal, Medicine, OL, Pharmaceutical industry

A randomized, controlled Phase 2b study of BPL-003 in TRD patients is underway with topline data expected in 2H 2024.

Key Points: 
  • A randomized, controlled Phase 2b study of BPL-003 in TRD patients is underway with topline data expected in 2H 2024.
  • Pivotal Trial 1 (COMP005) topline data is expected in the fourth quarter of 2024 and Pivotal Trial 2 (COMP006) topline data is anticipated mid-2025.
  • atai is dedicated to efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.
  • atai's vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life.

Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights

Retrieved on: 
onsdag, maj 8, 2024
FDA, Research, PTSD, MD, Depression, Webcast, TRD, Mental health, Patient, Pivotal, DSM-IV codes, Gold, Anorexia nervosa, Drug development, Therapy, CMPS, Pharmaceutical industry

Second quarter 2024 net cash used in operating activities is expected to be in the range of $32 million to $38 million.

Key Points: 
  • Second quarter 2024 net cash used in operating activities is expected to be in the range of $32 million to $38 million.
  • The Compass Pathways management team will host a conference call at 8:00am ET (1:00pm UK) on May 8, 2024.
  • A live webcast of the call will be available on Compass Pathway’s website at: First Quarter 2024 Financial Results .
  • The call will also be webcast on the Compass Pathways website and archived for 30 days.

SKYX to be a Main Event at TheRealDeal New York City Real-Estate Forum & Developer Showcase

Retrieved on: 
tisdag, maj 7, 2024
City, The Real Deal, Innovation, TRD, Lighting, Booth, Metropolitan Pavilion, Video game

SKYX will present its game changing smart home technology platform and products at Booth 2 and will host a management presentation at 3:30 pm at the Innovation Stage.

Key Points: 
  • SKYX will present its game changing smart home technology platform and products at Booth 2 and will host a management presentation at 3:30 pm at the Innovation Stage.
  • The Real Deal hosts and organizes the real estate industry’s largest events, including New York City, South Florida, and the Los Angeles Real Estate Showcase & Forums in addition to Future City, and TRD Brand Studio bespoke events.
  • As SKYX continues to enhance its market penetration, it will showcase its game-changing smart home platform technology to high-end real-estate developers and industry professionals.
  • Our technology enables an advanced and instant smart home solution that will significantly enhance real-estate value for both developers and homeowners.

GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates

Retrieved on: 
fredag, maj 3, 2024
FDA, Food, BDII, GHRS, Research, Psychiatry, New Drug Application, Insurance, TRD, Psychotherapy, IND, Patient, DSM-IV codes, Clinical trial, PD, G&A, Rat, Pharmaceutical industry

DUBLIN, Ireland, May 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the first quarter ended March 31, 2024, and provided updates on its business.

Key Points: 
  • DUBLIN, Ireland, May 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the first quarter ended March 31, 2024, and provided updates on its business.
  • We continue to expect GH001-PPD-203 completion and availability of top-line data in the third quarter of 2024.
  • R&D expenses were $8.7 million for the quarter ended March 31, 2024, compared to $7.3 million for same quarter in 2023.
  • G&A expenses were $2.9 million for the quarter ended March 31, 2024, compared to $3.1 million for the same quarter in 2023.

Toyota Establishes Hydrogen Headquarters to Accelerate Advancement of Fuel Cell Technology

Retrieved on: 
onsdag, maj 1, 2024
Hydrogen, TMNA, LPGA, National Renewable Energy Laboratory, FCD, Golden State, Toyota Motor Europe, Electricity, Research, Transport, TRD, Carbon, Fuel cell, PACCAR, CARB, Kenworth, PEM, Toyota Motor North America, Growth, Renewable energy

"Toyota has developed hydrogen fuel cell electric solutions for more than three decades, and we will continue to advance this scalable, zero-emission technology as part of our electrified portfolio," said Ted Ogawa, President and CEO, Toyota Motor North America.

Key Points: 
  • "Toyota has developed hydrogen fuel cell electric solutions for more than three decades, and we will continue to advance this scalable, zero-emission technology as part of our electrified portfolio," said Ted Ogawa, President and CEO, Toyota Motor North America.
  • "Renaming this facility as North American Hydrogen Headquarters represents our leadership in fuel cell development creating real-world products to help reduce carbon emissions."
  • Then, Toyota Motor Europe announced its own "Hydrogen Factory" with the aim to further grow Toyota's hydrogen business and stimulate wider roll-out of hydrogen ecosystems and infrastructure across Europe.
  • H2HQ will drive North American-led hydrogen initiatives and support the localization of global hydrogen-related technologies and products that include light-duty fuel cell applications, heavy-duty fuel cell opportunities, stationary fuel cell power generation, port vehicle applications and more.

Toyota Motor North America Announces New Leadership Structure

Retrieved on: 
tisdag, april 30, 2024
TMNA, Information technology, Sustainability, Human resources, Research, Marketing, Business development, Research and development, Carbon footprint, TRD, Inclusion, Customer service, Regulatory affairs, Toyota Motor North America, Growth, Management

PLANO, Texas, April 30, 2024 /PRNewswire/ -- Toyota Motor North America (TMNA) today announced executive leadership changes designed to drive continued growth, advance our commitment to vehicle electrification, and prepare for the future of mobility.

Key Points: 
  • PLANO, Texas, April 30, 2024 /PRNewswire/ -- Toyota Motor North America (TMNA) today announced executive leadership changes designed to drive continued growth, advance our commitment to vehicle electrification, and prepare for the future of mobility.
  • Jack Hollis and Chris Reynolds are assigned new roles and will continue to report to Ted Ogawa, chief executive officer, TMNA.
  • Jack Hollis, executive vice president of TMNA adds the role of chief operating officer, TMNA reporting to Ted Ogawa, chief executive officer.
  • Chris Reynolds, executive vice president of TMNA adds the role of chief strategy officer, TMNA reporting to Ted Ogawa.

atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression

Retrieved on: 
onsdag, april 24, 2024
Patient, Safety, Pharmacokinetics, Atypical depression, SSRI, TRD, Entrepreneurship, Depression, Treatment, MADRS, Pharmaceutical industry

The BPL-003 Phase 2a trial is an open-label study investigating BPL-003 as both monotherapy and adjunctive to SSRIs in patients with Treatment Resistant Depression.

Key Points: 
  • The BPL-003 Phase 2a trial is an open-label study investigating BPL-003 as both monotherapy and adjunctive to SSRIs in patients with Treatment Resistant Depression.
  • Part 2 of the study will investigate a single dose of BPL-003 in patients who are currently on a course of SSRI antidepressants.
  • The first patient has been dosed in Part 2 of the study and initial results are expected in H1 2025.
  • Initial data showed that a single dose of BPL-003 induced a rapid antidepressant response1 in 55% of patients on the day after dosing.

atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology

Retrieved on: 
onsdag, april 17, 2024
Safety, Pharmacokinetics, Atypical depression, EDI, TRD, Entrepreneurship, Patient, Treatment, PD, Journal, Pharmaceutical industry

Subjective psychedelic effects correlated with 5-MeO-DMT exposure and had a rapid onset and short duration, with acute effects resolving in less than two hours.

Key Points: 
  • Subjective psychedelic effects correlated with 5-MeO-DMT exposure and had a rapid onset and short duration, with acute effects resolving in less than two hours.
  • NEW YORK and BERLIN, April 17, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the publication of the Phase 1 results of BPL-003, Beckley Psytech’s novel, synthetic, intranasal benzoate salt formulation of 5-MeO-DMT, in The Journal of Psychopharmacology.
  • Participants across seven cohorts were given either a single dose of BPL-003 between 1 mg to 12 mg or a placebo.
  • Commenting on the publication, Florian Brand, CEO and Co-Founder of atai, said: “We are pleased by the publication of the BPL-003 Phase 1 data in the Journal of Psychopharmacology, a well-regarded, peer-reviewed journal.

Freedom Biosciences Announces FDA Approval of IND Application for FREE001 in Patients with Treatment-Resistant Depression

Retrieved on: 
torsdag, april 25, 2024
FDA, Brain, Yale University, Safety, Food, TRD, Therapy, Psychiatry, Patient, Freedom, SAN, Pharmaceutical industry

Freedom Bio will initiate its Phase 2a clinical trial (the "Study") in the first half of this year.

Key Points: 
  • Freedom Bio will initiate its Phase 2a clinical trial (the "Study") in the first half of this year.
  • This milestone marks a significant step forward in the development of FREE001, which has the potential to address a critical unmet medical need in patients suffering from TRD.
  • FREE001 builds on new ideas about brain mechanisms that limit the duration of ketamine efficacy.
  • Extending the duration and perhaps magnitude of ketamine efficacy could improve the safety, reduce patient burden of care, and expand access to this important treatment."